Quest Diagnostics (DGX) ebitda was $2.2B in FY2025 (+15% YoY). The tables below show the complete quarterly and annual ebitda history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual EBITDA
Fiscal Year
EBITDA
YoY
2025
$2.2B
+15%
2024
$1.9B
+8%
2023
$1.8B
-11%
2022
$2.0B
-31%
2021
$2.9B
+18%
2020
$2.4B
+51%
2019
$1.6B
+6%
2018
$1.5B
-2%
2017
$1.5B
-4%
2016
$1.6B
-10%
2015
$1.8B
+29%
2014
$1.4B
-24%
2013
$1.8B
+22%
2012
$1.5B
+15%
2011
$1.3B
-17%
2010
$1.6B
-6%
2009
$1.7B
+7%
2008
$1.6B
+12%
2007
$1.4B
Recent Quarterly EBITDA
Quarter
EBITDA
Q2 2026
$628M
Q1 2026
$566M
Q4 2025
$556M
Q3 2025
$554M
Q2 2025
$603M
Q1 2025
$508M
Q4 2024
$523M
Q3 2024
$481M
Q2 2024
$500M
Q1 2024
$438M
Q4 2023
$395M
Q3 2023
$472M
Source: DGX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.